Changes in HER3 expression profiles between primary and recurrent gynecological cancers.

Area of Science:

• Oncology
• Molecular Biology
• Gynecologic Oncology

Background:

• Human epidermal growth factor receptor-3 (HER3) is a receptor tyrosine kinase implicated in various cancers.
• HER3 overexpression correlates with poorer prognosis in several cancer types.
• The dynamic changes in HER3 expression from primary to recurrent gynecological cancers remain largely uncharacterized.

Purpose of the Study:

• To investigate the alterations in HER3 expression levels between primary and recurrent tumor tissues in gynecological cancers.
• To assess the clinical significance of HER3 expression changes in relation to patient outcomes.

Main Methods:

• Retrospective analysis of matched-pair tumor tissues from gynecological cancer patients at initial diagnosis and recurrence.
• Immunohistochemistry (IHC) was employed to assess HER3 expression.
• HER3 expression was categorized as "HER3-high" (IHC scores 2+ or 3+) or "HER3-low/zero" (IHC scores 0 or 1+).

Main Results:

• HER3 expression significantly increased in ovarian cancers (67.5% to 80.0%, p=0.004) and tended to increase in endometrial cancers (46.9% to 68.8%, p=0.08) from initial to recurrent stages.
• Cervical cancers showed stable HER3 expression (85.7% at both stages).
• Discordance rates in HER3 expression between initial and recurrent samples were 27.5% (ovarian), 53.1% (endometrial), and 14.3% (cervical).
• HER3-high status at recurrence was associated with shorter median survival in ovarian and endometrial cancers.

Conclusions:

• The proportion of patients with HER3-high expression rises from initial to recurrent diagnosis in major gynecological cancer types.
• Changes in HER3 expression during disease progression may represent a therapeutic vulnerability or resistance mechanism.
• Further research is warranted to elucidate the role of HER3 in gynecological cancer recurrence and treatment strategies.